Form 4: Immunic Inc. Executive Jason Tardio Acquires 500,000 Stock Options

Jason Tardio, President and COO of Immunic, Inc., was granted 500,000 stock options on July 12, 2024, according to a Form 4 filing with the SEC.

Summary

• Jason Tardio, the President and COO of Immunic, Inc., acquired 500,000 stock options on July 12, 2024.
• The exercise price of these options is $1.25.
• The options vest over time, with 25% vesting on July 12, 2025, and the remaining 75% vesting in 36 equal monthly installments.
• Vesting is contingent upon Tardio remaining an employee of Immunic, Inc. in good standing.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to executive compensation, and does not contain any information that would be considered particularly positive or negative. It's a neutral disclosure.

Future Outlook

The document does not contain any specific forward-looking statements or guidance for the company.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Executive compensation packages, including stock options, are standard practice in the biotech industry to incentivize performance and retain key personnel.
• Companies like Amgen, Gilead Sciences, and Biogen often use similar equity-based compensation strategies.
• The vesting schedule and exercise price are typical components of such grants, designed to align executive interests with long-term shareholder value.

Stakeholder Impact

• The granting of stock options to a key executive can align management's interests with those of shareholders, potentially driving long-term value creation.
• Employees may view this as a positive sign of investment in leadership.

Key Dates